浙江医药股份有限公司2026年第一季度报告详解
业绩下滑引发投资者关注，维生素主力产品价格承压
浙江医药股份有限公司（600216.SH）于2026年4月23日披露了其2026年第一季度财报，显示公司业绩出现较为明显的下滑，核心产品价格波动成为主因。以下为本次财报的详细解读，供投资者参考。
一、主要财务数据亮点
- 营业收入：21.91亿元，同比下降2.86%。
- 归属于上市公司股东的净利润：2.87亿元，同比下降29.84%。
- 扣除非经常性损益后的归母净利润：2.74亿元，同比下降31.89%。
- 利润总额：3.06亿元，同比下降32.47%。
- 经营活动产生的现金流量净额：1亿元，同比大幅下降67.20%。
- 基本每股收益：0.30元，同比下降30.23%。
- 加权平均净资产收益率：2.59%，同比减少1.18个百分点。
- 总资产：141.79亿元，较去年末增长0.62%。
- 归属于上市公司股东的所有者权益：112.41亿元，较去年末增长2.72%。
二、业绩下滑的主要原因
- 公司业绩下滑的核心原因在于主要产品维生素E、维生素A系列产品销售价格同比去年一季度下降。这直接导致营业收入与利润大幅下滑。
- 经营活动现金流量净额同比大幅减少，主要系报告期内收回出口退税减少。
三、非经常性损益项目
公司本期非经常性损益合计为1304.51万元，主要包括非流动性资产处置收益、政府补助、公允价值变动收益等，对公司整体盈利影响有限，主业表现才是业绩下滑的主要原因。
四、股东结构与持股情况
- 报告期末普通股股东总数为51,827户。
- 前十大股东持股比例相对集中，最大股东新昌县昌欣投资发展有限公司持股21.65%，国投高科技投资有限公司持股15.61%。
- 公司回购专用证券账户持有公司流通股数量为347.92万股，占比0.36%。
- 5%以上大股东之间不存在关联关系或一致行动。
五、资产负债表与现金流详情
- 货币资金：29.77亿元，较年初减少。
- 应收账款：15.92亿元，较年初增加，提示公司回款压力有所加大。
- 存货：17.97亿元，略有下降。
- 短期借款与长期借款：短期借款3.00亿元，长期借款5.04亿元，反映公司仍有一定的资金杠杆。
- 现金流情况：
- 经营活动现金流净额1亿元，较去年同期下降明显，主要原因是出口退税减少，以及购买商品和支付税费等支出增加。
- 投资活动现金净流出3.87亿元，显示公司在本期加大了投资力度，尤其是投资支付的现金和购建固定资产支出大幅增加。
- 筹资活动现金净流入1.27亿元，主要得益于取得的借款增加和子公司吸收少数股东投资。
- 期末现金及现金等价物余额29.77亿元。
六、对股东和投资者的重要提醒与潜在影响
- 本季度公司业绩大幅下滑，主要产品价格承压，对公司未来盈利能力构成不确定性，或将影响市场对公司估值预期，具有较强的价格敏感性。
- 公司经营性现金流下滑明显，短期内资金回笼压力加大，需持续关注公司应收账款和存货管理能力。
- 公司加大投资支出，若新投资不能及时产生效益，未来财务压力可能进一步加大。
- 股东结构稳定，无大股东集中减持或显著变化，但持股较为集中，市场波动时需关注大股东动态。
七、结论
浙江医药2026年第一季度财报反映出主营产品价格下滑带来的业绩压力，现金流状况也趋于紧张。后续公司如何应对产品价格波动、提升核心竞争力及改善现金流，将直接影响公司股价表现。建议投资者密切关注公司后续公告以及行业价格走势。
免责声明：本文为参考财报内容整理和分析，仅供投资者决策参考，不构成任何投资建议。股市有风险，投资需谨慎。
Zhejiang Medicine Co., Ltd. Q1 2026 Results: Significant Profit Decline Amid Core Product Price Pressure
Key Highlights and Potential Share Price Impact
Zhejiang Medicine Co., Ltd. (600216.SH) released its Q1 2026 earnings report on April 23, 2026, showing a marked decline in performance, mainly due to falling prices of its core vitamin products. The details below provide an in-depth analysis for investors.
1. Key Financial Highlights
- Revenue: RMB 2.191 billion, down 2.86% year-on-year.
- Net profit attributable to shareholders: RMB 287 million, down 29.84% YoY.
- Net profit after extraordinary items: RMB 274 million, down 31.89% YoY.
- Total profit: RMB 306 million, down 32.47% YoY.
- Net operating cash flow: RMB 100 million, down 67.20% YoY.
- Basic EPS: RMB 0.30, down 30.23% YoY.
- ROE (weighted average): 2.59%, down 1.18 percentage points YoY.
- Total assets: RMB 14.179 billion, up 0.62% from year-end.
- Shareholders’ equity: RMB 11.241 billion, up 2.72% from year-end.
2. Reasons for Profit Decline
- Main cause: Significant YoY drop in sales prices of core products Vitamin E and Vitamin A series, causing both revenue and profit to fall sharply.
- Operating cash flow also dropped sharply, primarily due to reduced export tax rebates during the period.
3. Non-Recurring Items
Non-recurring profit totaled RMB 13 million, mainly from asset disposals, government subsidies, and fair value gains—these had limited impact on overall earnings, with core business being the main drag on profits.
4. Shareholder Structure
- Ordinary shareholders at quarter end: 51,827.
- Top 10 shareholders are relatively concentrated, with the largest holding 21.65% and the second largest 15.61%.
- The company holds 3.48 million treasury shares (0.36%).
- No related party relationships among 5%+ shareholders.
5. Balance Sheet & Cash Flow Details
- Cash: RMB 2.977 billion, down from year start.
- Accounts receivable: RMB 1.592 billion, up, indicating rising collection pressure.
- Inventory: RMB 1.797 billion, slightly down.
- Short/Long-term borrowings: RMB 300 million/504 million, reflecting ongoing leverage usage.
- Cash flow:
- Net operating cash flow RMB 100 million, sharply lower mainly due to less export tax rebate and higher payments for goods and taxes.
- Net investing cash outflow RMB 387 million, indicating increased investment spending, especially on fixed assets and investments.
- Net financing cash inflow RMB 127 million, mainly from new borrowings and minority shareholder investments.
- Ending cash and equivalents: RMB 2.977 billion.
6. Investor Alerts & Potential Share Price Sensitivity
- The significant decline in core product prices has led to marked profit and cash flow drops, directly impacting earnings expectations and carrying strong price sensitivity.
- Operating cash flow deterioration and increased collection and inventory management pressures warrant close attention.
- The company’s increased investment spending could heighten future financial pressure if returns are not quickly realized.
- Shareholder structure remains stable, but high concentration means market should monitor major holder moves during volatility.
7. Conclusion
Zhejiang Medicine’s Q1 2026 results show the impact of falling vitamin prices on earnings and cash flow. How the company manages product price volatility, cash flow, and new investment returns will directly affect future share price performance. Investors are urged to monitor follow-up disclosures and industry pricing trends.
Disclaimer: This article is for informational and analytical purposes only, and does not constitute investment advice. Stock investment involves risks, and investors should proceed with caution.
View 浙江医药 Historical chart here
